RxDoctor Payments DataLook up a doctor →

Kara Boutwell

Family · Mobile, ALNPI 1275941601

Payments from drug & device makers

$12,209in general payments, 2019–2025

Across 641 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$1K
  • Merck$1K
  • Johnson & Johnson$628
  • Daiichi Sankyo Inc.$605
  • Incyte Corporation$483
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$12,209100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis78$1,488
AstraZeneca(2 entities)62$1,025
Merck49$1,008
Johnson & Johnson36$628
Daiichi Sankyo Inc.27$605
Incyte Corporation28$483
Amgen25$482
E.r. Squibb & Sons, L.L.C.29$470
Eisai Inc.24$459
Lilly USA, LLC27$448
Bristol Myers Squibb18$431
Pfizer24$378
Genentech USA, Inc.17$291
Regeneron Healthcare Solutions, Inc.11$277
Sanofi13$271
Astellas Pharma US Inc14$264
GSK14$237
Exelixis Inc.13$233
Myriad Genetic Laboratories, Inc.4$221
Ipsen Biopharmaceuticals, Inc6$149
Takeda Pharmaceuticals U.S.A., Inc.6$146
Deciphera Pharmaceuticals Inc.7$124
Beigene USA, Inc.8$118
Blueprint Medicines Corporation5$115
Array Biopharma Inc6$109
Pharmaessentia USA Corporation4$107
Seagen Inc.6$105
AbbVie4$90
Boehringer Ingelheim4$87
Puma Biotechnology, Inc.5$82
Beone Medicines USA, Inc.4$78
Coherus Oncology, Inc.3$65
TG Therapeutics, Inc.3$61
Genmab U.S., Inc.3$55
Pharmacosmos Therapeutics Inc.2$53
EMD Serono, Inc.3$50
Kyowa Kirin, Inc.2$50
Sumitomo Pharma America, Inc.3$50
Stemline Therapeutics Inc.2$47
Bayer3$45
Gilead(2 entities)2$45
Heron Therapeutics, Inc.1$41
Sobi, Inc2$40
Acrotech Biopharma Inc.2$37
Tersera Therapeutics LLC2$36
G1 Therapeutics, Inc.2$35
Mirati Therapeutics, Inc.2$35
AVEO Pharmaceuticals, Inc.2$35
Caris MPI, Inc.2$34
Morphosys, US Inc.2$33
Cumberland Pharmaceuticals, Inc.2$31
Karyopharm Therapeutics Inc.2$31
Azurity Pharmaceuticals, Inc.2$31
Servier Pharmaceuticals LLC2$30
Adaptive Biotechnologies Corporation1$27
Tempus AI, Inc1$25
Immunogen, Inc.1$25
Epizyme, Inc.1$24
Veracyte, Inc.1$20
Spectrum Pharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,209 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$16,620
Medicare patients
169
Services billed
1,465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl11$27,202
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen141$4,356
Fentanyl14$2,338
Morphine Sulfate ErMorphine Sulfate50$1,561
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$1,354
Letrozole46$1,077
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine30$806
Gabapentin74$804
Morphine Sulfate27$705
Anastrozole21$531
Oxycodone Hcl20$486
Acyclovir17$301
Hydroxyurea16$279
Olanzapine14$176
Ondansetron Hcl17$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$448$17614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →